Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 12:13:1063413.
doi: 10.3389/fphar.2022.1063413. eCollection 2022.

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Nurul Annisa  1   2 , Melisa I Barliana  1   3 , Prayudi Santoso  4 , Rovina Ruslami  5
Affiliations
Review

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Nurul Annisa et al. Front Pharmacol. .

Abstract

Tuberculosis (TB) is an infectious disease that occurs globally. Treatment of TB has been hindered by problems with multidrug-resistant strains (MDR-TB). Fluoroquinolones are one of the main drugs used for the treatment of MDR-TB. The success of therapy can be influenced by genetic factors and their impact on pharmacokinetic parameters. This review was conducted by searching the PubMed database with keywords polymorphism and fluoroquinolones. The presence of gene polymorphisms, including UGT1A1, UGT1A9, SLCO1B1, and ABCB1, can affect fluoroquinolones pharmacokinetic parameters such as area under the curve (AUC), creatinine clearance (CCr), maximum plasma concentration (Cmax), half-life (t1/2) and peak time (tmax) of fluoroquinolones.

Keywords: ABCB1; SLCO1B1; UGT1A1; UGT1A9; moxifloxacin; pharmacogenetics; sitafloxacin; trovafloxacin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Fluoroquinolones pharmacokinetic parameter affected by gene polymorphisms.
See this image and copyright information in PMC

References

    1. Almazroo O. A., Miah M. K., Venkataramanan R. (2017). Drug metabolism in the liver. Clin. Liver Dis. 21, 1–20. 10.1016/j.cld.2016.08.001 - DOI - PubMed
    1. Balram C., Sabapathy K., Fei G., Khoo K. S., Lee E. J. D. (2002). Genetic polymorphisms of UDP-glucuronosyltransferase in asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics 12 (1), 81–83. 10.1097/00008571-200201000-00012 - DOI - PubMed
    1. Belle D. J., Singh H. (2008). Genetic factors in drug metabolism. Am. Fam. Physician 77 (11), 1553–1560. - PubMed
    1. Belmonte C., Ochoa D., Roman M., Saiz-Rodriguez M., Wojnicz A., Gomez-Sanchez C. I., et al. (2018). Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122 (6), 596–605. 10.1111/bcpt.12960 - DOI - PubMed
    1. Cardoso A. R., Queliconi B. B., Kowaltowski A. J. (2010). Mitochondrial ion transport pathways: Role in metabolic diseases. Biochim. Biophys. Acta 1797 6 (7), 832–838. 10.1016/j.bbabio.2009.12.017 - DOI - PubMed

LinkOut - more resources